Robert Figlin, MD, FACP
Dr. Figlin received his medical degree from the Medical College of Pennsylvania, completed his residency in internal medicine at Cedars-Sinai Medical Center and a fellowship in hematologyoncology at the David Geffen School of Medicine at UCLA. He joined the faculty of UCLA in 1982 as assistant professor of medicine in the Division of Hematology-Oncology and was appointed co-director of the Jonsson Comprehensive Cancer Center’s Oncology Program in 1993. He also held the post of medical director of the Thoracic and Genitourinary Oncology Program in the Departments of Medicine, Surgery and Urology, and served as program director of Solid Tumor Development Therapeutics within Jonsson.
Dr. Figlin serves as chairman of the UCLA Medical Institutional Review Board and as a member of the UCLA Human Research Policy Board. He is board certified in medical oncology and internal medicine, a fellow in the American College of Physicians, and a member of many professional societies including the American Urological Association and American Society of Clinical Oncology. An author of numerous studies published in journals such as JAMA, Journal of Clinical Oncology and Annals of Internal Medicine, Figlin also serves as editor for the peer-reviewed journals, Kidney Cancer Journal and Bladder Cancer Journal, and is on the editorial board of Cancer Therapeutics and Cancer Biotherapy and Radiopharmaceuticals, among others.
A national leader in genitourinary and thoracic oncology, his research interests include cell, immune, genetic and targeted therapies in solid tumor oncology, with emphasis in renal cell carcinoma and thoracic oncology research.
Francis Giles, MB, MD, FRCPI, FRCPath
Dr. Giles, who came to CTRC from M. D. Anderson Cancer Center in Houston, has focused his clinical and research efforts on providing therapy for patients suffering from treatmentresistant or pervasive disease. His interests include lymphomas, multiple myeloma, developmental therapeutics, stem cell transplantation, and leukemias.
An extraordinary researcher and clinical scientist, Dr. Giles served as principal investigator on numerous clinical studies of many novel agents. He was the first to use interferonbased combination regimens as a means of treating chronic myeloid leukemia and to show the effect of alpha interferon in essential thrombocythemia. He has published more than 375 peer reviewed articles related to hematological disorders in leading scientific journals including the New England Journal of Medicine, Journal of Clinical Oncology, British Journal of Haematology, Cancer, and Lancet.
Additionally, Dr. Giles is the founder and chairman of the International Oncology Study Group, a cooperative research group created in 1993 and composed of more than 170 oncologists from 90 institutions throughout the U.S., Australia, China, New Zealand, the Philippines, South Korea, Thailand, Singapore, Taiwan, South Africa, Saudi Arabia, and several Middle Eastern countries. It is organized to conduct clinical therapeutic studies aimed at improving the prognosis of cancer patients. Now in San Antonio, Dr. Giles is building on the IDD’s international reputation for Phase I clinical and preclinical pharmacology studies of novel anticancer drugs by adding Phase I/II/III studies of novel agents for patients with hematological malignancies while expanding our existing programs focused on solid tumors.
Alain Mita, MD
Dr. Mita received his medical degree from the University “Carol Davilla” Bucharest, Romania. He completed his fellowship training in 2006 at the CTRC Institute for Drug Development and University of Texas Health Science Center and is currently a Principal Investigator at the CTRC Institute for Drug Development. He is also an Assistant Professor of Medicine at the University of Texas Health Science Center and a medical oncologist at the Audie L. Murphy Veteran Administration Hospital in San Antonio, Texas. Dr. Mita received the ASCO Merit Award in 2005 and 2006 and the AACR Scholar-in- Training Award for the 2005 AACR-NCI-EORTC. He is a member of the editorial board for Targeted Oncology. He is Co-Principal Investigator on 17 phase I-II studies. He has co-authored 13 articles and 48 abstracts.
Monica Mita, MD
Dr. Mita received her medical degree from the University “Carol Davilla” Bucharest, Romania. She completed an Advanced Oncology Drug Development Fellowship at the University of Texas Health Science Center, Division of Medical Oncology and Cancer Therapy and Research Center. Dr. Mita is a Clinical Investigator with Cancer Therapy and Research Center and an Assistant Professor of Medicine at University of Texas Health Science Center at San Antonio. She received the ASCO 2005 Merit Award and received a Cancer Center Council Grant for “Multitargeted approach of intracellular signaling for cancer cells in vitro and in vivo. She has co-authored 17 articles and 43 abstracts. She is the Principal Investigator on 7 research grants and Co-principal investigator in phase I-II studies involving 11 compounds.
Alan B. Sandler, MD
Alan B. Sandler is Associate Professor of Medicine in the Division of Hematology/Oncology at Vanderbilt University Medical Center in Nashville, Tennessee. He also serves as the Medical Director of the Thoracic Oncology Program and the Director of the Vanderbilt-Ingram Cancer Center Affiliate Network (VICCAN), a partnership of community-based oncologists who offer patients clinical trials.
After earning a B.S. in Pharmacy (cum laude) at the University of Toledo in Ohio and an M.D. at Rush Medical College in Chicago, Dr. Sandler completed an internship and residency in Internal Medicine at Yale-New Haven Hospital and a Fellowship in Medical Oncology at the Yale University School of Medicine in New Haven, Connecticut. His academic honors include membership in Alpha Omega Alpha and Rho Chi, the medical and pharmaceutical honor societies.
He is an active member of the American Society of Clinical Oncology and the Eastern Cooperative Oncology Group where he serves as the Co-Chair of the Thoracic Committee. Dr. Sandler currently serves as Chairman or Co-Chairman of several Phase I, II, and III studies focusing on the activity of single or combined chemotherapy drugs and/or combined treatments for lung, esophageal, sarcoma and refractory cancers. Dr. Sandler serves as a consultant to several pharmaceutical companies. In addition, he serves on the editorial boards of American Journal of Clinical Oncology, Clinical Lung Cancer and the Japanese Journal of Clinical Oncology, and is a reviewer for several journals including The New England Journal of Medicine, the Journal of Clinical Oncology, Cancer Investigations, Cancer Therapeutics, Cancer, the British Journal of Cancer, and the European Respiratory Journal. Dr. Sandler is the author or co-author of more than 100 published articles, book chapters, reviews, and abstracts involving the pharmacology and clinical activity of chemotherapy and novel non-chemotherapy agents over a broad spectrum of tumor types.
Susan Smith, MSN
Susan Smith, MSN, is currently Senior Director, Oncology Clinical Operations, NA, at AAIPharma. She has over 25 years of extensive oncology drug development experience including clinical oncology patient care, research site management, CRO trial management, and successful pharmaceutical regulatory submissions. She obtained her masters degree from the University of Texas Health Science Center in San Antonio, TX. Formally, she was Clinical Operations Director at ILEX Inc, (now Genzyme. Inc) where she managed personnel involved in multiple projects in a variety of therapeutic areas such as breast, colon, Aids related NHL, bladder, lung, melanoma, ALL / AML (pediatrics and adults), and CLL She also served as Director of Education and Training providing SOP and oncology therapeutic training to clinical staff. She was instrumental in the development of strategic and tactical plans and operational systems for ILEX’s pharmaceutical division. Her experience also included Program Management for product development from IND to NDA preparation and approvals, orphan drug applications, ODAC meetings and other regulatory submissions. Previous to ILEX, Susan was Associate Director at the Institute for Drug Development/ CTRC San Antonio, TX where she managed clinical site research personnel and studies from early to late stage development for multiple sponsors. Her clinical oncology nursing experience includes bone marrow transplant, apheresis, Phase I – IV clinical studies, and supportive care. She has coordinated multiple Independent Response Review Panels and Data Safety Monitoring Boards including two products that subsequently obtained marketing approval.
Daniel Von Hoff, MD, FACP
Daniel D. Von Hoff, M.D., is currently Professor of Medicine, Pathology, Molecular and Cellular Biology, Director of the Arizona Health Sciences Center’s Cancer Therapeutics Program, Executive Vice President, Translational Genomics Research Institute (TGen), Director, TGen’s Translational Drug Development Division and Head, Pancreatic Cancer Research Program. He is also Chief Scientific Officer for US Oncology.
Dr. Von Hoff’s major interest is in the development of new anticancer agents, both in the clinic and in the laboratory. He and his colleagues were involved in the beginning of the development of many of the agents we now use routinely, including: mitoxantrone, fludarabine, paclitaxel, docetaxel, gemcitabine, CPT-11, and others.
Dr. Von Hoff’s laboratory interests and contributions have been in the area of in vitro drug sensitivity testing to individualize treatment for the patient. Dr. Von Hoff has published more than 515 papers, 127 book chapters, and more than 850 abstracts.
Dr. Von Hoff was appointed to President Bush’s National Cancer Advisory Board in June 2004 – March 2010. Dr. Von Hoff is the past President of the American Association for Cancer Research, a Fellow of the American College of Physicians, and a member and past board member of the American Society of Clinical Oncology. He is a founder of ILEXTM Oncology, Inc. (recently acquired by Genzyme). He is founder and the Editor Emeritus of Investigational New Drugs – The Journal of New Anticancer Agents; and, Editor-in-Chief of Molecular Cancer Therapeutics. He is also proud to have been a mentor and teacher for multiple medical students, medical oncology fellows, graduate students, and post-doctoral fellows.
Colonel Stacy Young-McCaughan, RN, PhD
Colonel Young-McCaughan is Chief, Department of Clinical Investigations & Consultant to the Surgeon General for Nursing Research at Brooke Army Medical Center, Fort Sam Houston, Texas.
Colonel Young-McCaughan has practiced nursing for 26 years. She was one of the very early persons to investigate aerobic exercise and quality of life in women with breast cancer. Stacey has completed over a decade of research. Her program of research continues to focus on exercise and women who have survived breast cancer.
She was presented the Yale University School of Nursing Distinguished Alumna Award for 2004. Twice she has received the prestigious Phyllis J. Verhonick Award for Nursing Research. Her findings have been published in Oncology Nursing Forum, Cancer Nursing, New Zealand Nursing Forum, and Pain Management Nursing.
Additionally, Dr. Young-McCaughan has addressed forums, convened by members of Congress, concerning United States Department of Defense funding for breast cancer, ovarian cancer, and prostate cancer research. She played a pivotal role in securing critical funding from the Department of Defense for cancer research.
|
Home
